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Longitudinal assessment of tumor development
using cancer avatars derived from genetically
engineered pluripotent stem cells
Tomoyuki Koga 1,2,9, Isaac A. Chaim 3,5,9, Jorge A. Benitez 1, Sebastian Markmiller3, Alison D. Parisian1,4,
Robert F. Hevner4, Kristen M. Turner1, Florian M. Hessenauer1, Matteo D’Antonio 5, Nam-phuong D. Nguyen6,
Shahram Saberi7, Jianhui Ma1, Shunichiro Miki1, Antonia D. Boyer1, John Ravits7, Kelly A. Frazer 5,8,
Vineet Bafna6, Clark C. Chen2, Paul S. Mischel 1,4, Gene W. Yeo3,5* & Frank B. Furnari 1,4*
Many cellular models aimed at elucidating cancer biology do not recapitulate pathobiology
including tumor heterogeneity, an inherent feature of cancer that underlies treatment
resistance. Here we introduce a cancer modeling paradigm using genetically engineered
human pluripotent stem cells (hiPSCs) that captures authentic cancer pathobiology. Ortho-
topic engraftment of the neural progenitor cells derived from hiPSCs that have been genome-
edited to contain tumor-associated genetic driver mutations revealed by The Cancer Genome
Atlas project for glioblastoma (GBM) results in formation of high-grade gliomas. Similar to
patient-derived GBM, these models harbor inter-tumor heterogeneity resembling different
GBM molecular subtypes, intra-tumor heterogeneity, and extrachromosomal DNA amplifi-
cation. Re-engraftment of these primary tumor neurospheres generates secondary tumors
with features characteristic of patient samples and present mutation-dependent patterns of
tumor evolution. These cancer avatar models provide a platform for comprehensive long-
itudinal assessment of human tumor development as governed by molecular subtype
mutations and lineage-restricted differentiation.
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Effective modeling of cancer has been a conceptual corner-stone in the field of oncology for studying pathobiology andidentifying therapeutic targets. In the case of glioblastoma
(GBM), the most common primary malignant tumor of the
central nervous system1, mouse models of GBM-like tumors
generated through the genetic disruption of different combina-
tions of core tumor suppressors and/or by introduction of
oncogenes such as Src, K-ras, H-ras, PDGFB, and EGFRvIII2 are
available to investigate the biology of these aggressive tumors or
to test possible treatments in preclinical settings3. These mouse
models are suitable to investigate pathology of genetically defined
gliomas and useful for drug testing, but typically lack the intra-
tumor heterogeneity that is observed in human gliomas4. In
addition, while human astrocytes engineered with combinations
of human TERT and H-Ras expression and inhibition of the TP53
pathway either by SV40 T/t-Ag or by HPV E6 and E7 generate
gliomas with high-grade histology5,6, how well these models
recapitulate the full spectrum of glioma pathobiology, especially
in terms of GBM heterogeneity, has not been well defined. In
contrast, patient-derived xenografts (PDX) have been useful to
study inter- and intra-tumoral heterogeneity7,8 and sensitivity to
pathway-specific therapies9, however, they do not allow for
experimental standardization or afford analysis of the effects of
molecular subtype mutations on tumor evolution.
The progress in human stem-cell technologies and genome
editing using site-specific nucleases such as ZFN, TALEN, and
CRISPR/Cas9 has broadened the field of human disease model-
ing10. Such engineering has also been efficiently applied to neural
stem cells providing opportunities for functional genetic analy-
sis11. This combination of human stem cell and genome editing
promises great potential when applied to cancer models. The first
such model generated utilized colon organoids derived from
human intestinal crypt stem cells engineered with four or five
mutations common in colorectal cancers12,13. These organoid
models accurately predict drug responses and their utility is
anticipated for application of personalized therapies14. Later, a
brain tumor model deleted for PTEN by TALEN-mediated
homologous recombination led to the reprograming of human
neural stem cells toward a cancer stem cell-like phenotype15.
However, it remains unknown if these cancer models generated
through genome editing harbor authentic pathological features of
cancers, including tumor heterogeneity and clonal evolution.
Here, we establish a robust platform in an isogenic back-
ground, which uses CRISPR/Cas9 genome editing technology and
serial in vivo engraftments enabling longitudinal assessment of
human high-grade glioma (HGG) models containing combina-
tions of genetic alterations observed in proneural and mesench-
ymal GBM molecular subtypes. We further present how closely
these models recapitulate pathobiology of the disease and discuss
their utility as an avatar platform for future studies on tumor
biology and evolution.
Results
Neural progenitors with GBM mutations form HGG-like
tumors. We first introduced two different combinations of dri-
ver mutations into human induced pluripotent stem cells (iPSCs)
by CRISPR/Cas9 genome editing16,17 (Fig. 1a, b). One combi-
nation of deletions targeted tumor suppressor genes PTEN and
NF1, which are commonly altered together in the mesenchymal
subtype of GBM18,19. A second combination of deletions targeted
TP53 and exons 8 and 9 of PDGFRA (PDGFRAΔ8–9). This creates
a constitutively active truncating PDGFRA mutation observed in
40% of PDGFRA amplified GBM20, resulting in a genotype
commonly found in the proneural subtype of isocitrate
dehydrogenase-wildtype GBM18,19. The genetic modifications in
single clones were confirmed by genotyping PCR (Fig. 1c) and
RT-qPCR (Fig. 1d). Edited iPSC clones with desired mutations
were differentiated into neural progenitor cells (NPCs), using a
small molecule protocol21 and differentiation status was con-
firmed by downregulation of pluripotency markers, Nanog and
Oct4, and corresponding upregulation of NPC markers, Pax6,
Nestin, and Sox1 (Fig. 1e). These edited NPCs were expanded on
matrigel-coated plates in NPC maintenance media21 and were
utilized in further experiments.
We next evaluated if these genetically modified NPCs were
capable of forming orthotopic tumors in immunocompromised
mice (Fig. 1a). When edited NPCs were engrafted in the brains of
four Nod scid mice, PTEN−/−;NF1−/− NPCs and TP53−/−;
PDGFRAΔ8–9 NPCs each formed brain tumors with median
survival of 141, and 119.5 days, respectively (Fig. 1f). Pathological
assessment of PTEN−/−;NF1−/− tumors revealed regions of
hypercellularity with occasional mitoses (Fig. 2a), and in one out
of four tumors, there were biphasic dense glial and loose
mesenchymal/sarcoma morphologies, typical of gliosarcoma
(Fig. 2b). In addition, regions of necrosis (Fig. 2c), vascular
endothelial proliferation (Fig. 2d), subarachnoid spread (Fig. 2e),
perineuronal satellitosis, and subpial accumulation of tumor cells
(Fig. 2f), were also apparent. The tumors were consistently
positive for GFAP (3+ in 6/6 high power fields) (Fig. 2g,
Supplementary Fig. 2a) and Olig2 (3+ in 4/6 high power fields,
2+ in 2/6 high power fields) (Fig. 2h, Supplementary Fig. 2b), and
highly proliferative as indicated by Ki-67 staining (35.44 ±
1.435%; mean ± SEM) (Fig. 2i, Supplementary Fig. 2c). TP53−/−;
PDGFRAΔ8–9 tumors presented nodular growth of a primitive
neuronal component (dark purple) intermingled with glial
components (Fig. 2j), rosettes with neuropil-like texture (Fig. 2k),
a serpiginous zone of pseudopalisading necrosis (Fig. 2l), and
intraventricular growth (Fig. 2m). These tumors were positive for
GFAP (3+ in 6/6) (Fig. 2n, Supplementary Fig. 2a) and Olig2 (3+
in 6/6) (Fig. 2o, Supplementary Fig. 2b), and also highly positive
for Ki-67 staining (27.79 ± 5.731%; mean ± SEM) (Fig. 2p,
Supplementary Fig. 2c). In terms of WHO grade, three and one
out of four tumors were scored as grade 4 and grade 3,
respectively for PTEN−/−;NF1−/− tumors, and four out of four
tumors were scored as grade 4 for TP53−/−;PDGFRAΔ8–9 tumors
(Supplementary Fig. 3). In contrast, PTEN−/− and TP53−/−
singly edited NPCs did not form tumors in the brain over the
same time span (Fig. 1f, Supplementary Fig. 4a, b), while unedited
iPSCs formed teratoma-like tumors (Supplementary Fig. 5). Lack
of teratomas after NPC injection suggests a high efficiency of
differentiation to NPCs. These results illustrate that using this
modeling paradigm, small numbers of known driver mutations
found in GBM are sufficient for phenotypic recapitulation of
human HGG tumors.
iHGG cells can be cultured and form secondary tumors. One of
the benefits of using PDX models in cancer research is that they
can be cultured in vitro and be re-engrafted in animals, thus
enabling both in vitro and in vivo analyses22. We evaluated if our
induced HGG (iHGG) models could be used in a similar manner.
Dissociated tumors obtained from the mouse brains were sorted
for human cells using a human MHC antibody, followed by
propagation of isolated cells in the same neurosphere conditions
used for GBM PDX spheres23, which confirmed iHGG sphere
formation capability (Fig. 3a). These iHGG spheres possessed the
same genotypes as the corresponding input NPCs (Supplemen-
tary Fig. 6). Extreme limiting dilution assays24 showed that iHGG
spheres had greater self-renewal capacity, a feature of cancer stem
cells, when compared to pre-engraftment NPCs (Fig. 3b), again
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highlighting gain of cancerous phenotypes of iHGG cells com-
pared to original input cells.
We then evaluated if these iHGG-derived sphere cells maintained
tumorigenic capacity by secondary orthotopic engraftment (Fig. 3c).
When injected in the brains of Nod scid mice, PTEN−/−;NF1−/−
and TP53−/−;PDGFRAΔ8–9 iHGG-derived sphere cells formed
tumors with a shortened latency period of median 76.5 days and
34.5 days, respectively (p= 0.0005, log-rank test) (Supplementary
Fig. 7). We also tested if these models can be used for in vivo drug
treatment experiments comparable to those applied to PDX lines
by treating orthotopically engrafted animals with temozolomide
(TMZ), a DNA-alkylating chemotherapeutic agent used for standard
care treatment of GBM patients25. TP53−/−;PDGFRAΔ8–9 iHGGs
proved to be more sensitive to TMZ compared to PTEN−/−;NF1−/−
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Fig. 1 Different iHGG models derived from edited human iPSCs. a Schema of iHGG generation. b Designs for gene editing indicating placement of
sgRNAs. c Genotyping PCR and d Semi-quantitative RT-qPCR evaluating designated edits. Data are representative of three replicates, n= 3. Data are
represented as mean ± SD. e RT-qPCR results of markers for iPSCs and NPCs. Data are representative of three replicates, n= 3. Data are represented as
mean ± SD. f Kaplan–Meier curves showing survival of mice engrafted with (left) PTEN−/− NPCs, PTEN−/−;NF1−/− NPCs, (right) TP53−/− NPCs, and
TP53−/−;PDGFRAΔ8–9 NPCs. Statistical significance was evaluated by the log-rank test. n= 4 animals for each arm for each model. Source data are
provided as a Source Data file.
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iHGGs (Fig. 3d). PTEN−/−;NF1−/− iHGGs were found to
express higher levels of O6-methylguanine DNA methyl
transferase (MGMT) (Fig. 3e), which is associated with resistance
to TMZ in GBM patients26, compared to TP53−/−;PDGFRAΔ8–9
iHGGs. An alternative explanation of this differential sensitivity,
through MGMT-independent mechanisms in the context of
TP53 alteration27,28 cannot be eliminated.
iHGGs recapitulate molecular and genetic hallmarks of GBM.
We further investigated if these iHGGs showed inter- and intra-
tumor heterogeneity, which is another hallmark of GBM and
cancer in general29. This important feature of cancer has not been
well studied in previous models to date. To investigate the
robustness of our iHGG models we performed in triplicate,
single-cell RNA sequencing (scRNA-seq) using primary iHGG
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spheres, secondary iHGG tumor cells obtained from orthotopic
injection of the primary spheres, as well as secondary spheres
derived by in vitro culture of the secondary tumor cells for both
genotypes, for a total of 14 samples (Fig. 4a).
Visual analysis of all the samples by Uniform Manifold
Approximation and Projection (UMAP) reveals clear structural
stratification between primary and secondary spheres of the same
genotype as well as between spheres and tumors (Fig. 4b).
However, the greatest variation appears between the two iHGG
models of different genotypes. This inter-tumor heterogeneity
between iHGG models was not apparent in pre-engraftment
NPCs with different gene edits (Supplementary Fig. 8). In fact, the
Fig. 2 Histology of iHGGs. H&E staining of PTEN−/−;NF1−/− iHGGs showing a region of hypercellularity infiltrated by irregular, elongated to angulated
tumor cells with occasional mitoses (a), scale bars, 50 μm (left) and 10 μm (right), biphasic dense (glial) and loose (mesenchymal/sarcoma)
morphologies, typical of gliosarcoma (b), necrosis (central pink zone) with peripheral “pseudopalisading” of cells around the necrotic center (c), scale bars,
200 μm (b, c), vascular endothelial proliferation (d), scale bar, 100 μm, rupture through the pial surface, and consequently subarachnoid spread (upper
right) (e), scale bar, 200 μm, and “secondary structures” typical of glioma, including perineuronal satellitosis and subpial accumulation of tumor cells (f),
scale bar, 50 μm. GFAP (g), Olig2 (h), Ki-67 (i) staining of PTEN−/−;NF1−/− iHGGs, scale bars, 100 μm (g–i). H&E staining of TP53−/−;PDGFRAΔ8–9 iHGGs
showing nodular growth of a primitive neuronal component (dark purple) intermingled with glial component (pink) (j), scale bar, 200 μm, rosettes with
neuropil-like texture in a primitive neuronal component (k), scale bar, 50 μm, a serpiginous zone of pseudopalisading necrosis (l), scale bar, 200 μm, and a
tumor rupture through ependyma illustrating intraventricular growth (m), scale bar, 500μm. GFAP (n), Olig2 (o), Ki-67 (p) staining of TP53−/−;
PDGFRAΔ8–9 iHGGs, scale bars, 100 μm (n–p).
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strongest driver of transcriptomic differences is genotype, as
shown by the clear split between them, regardless of their origin
(spheres or tumors, primary or secondary) for the strongest
principal component (PC), pc1 (Fig. 4c). These findings continue
to support the notion that a small number of driver mutations are
sufficient for the development of such pathognomonic inter-
tumor heterogeneity that arises through the process of
transformation.
Given that our models were engineered to recapitulate different
clinical GBM molecular subtypes, specifically proneural and
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mesenchymal, we sought to determine if our samples manifested
transcriptomic GBM signatures as established previously8,18.
TP53−/−;PDGFRAΔ8–9 iHGG show upregulation of genes
characteristic of the proneural subtype, while the PTEN−/−;
NF1−/− iHGG show a mesenchymal subtype signature for both
spheres and tumors (Fig. 4d, and Supplementary Fig. 9). Subtype
scores involving all expressed genes under each subtype show
similar trends, with higher proneural scores for TP53−/−;
PDGFRAΔ8–9 iHGG and higher mesenchymal scores for
PTEN−/−;NF1−/− iHGG (Supplementary Fig. 10). Interestingly,
TP53−/−;PDGFRAΔ8–9 iHGG samples also show increased
classical subtype scores. Importantly, when examined at single-
cell resolution, each sample shows intra-tumor heterogeneity with
different populations of cells presenting signatures of different
subtypes (Supplementary Fig. 10), as is characteristic of GBM
patient samples29. In addition, all samples are comprised of
populations of cycling and noncycling cells (Supplementary
Fig. 11a, b), which is also characteristic of patient samples and is
in juxtaposition with other in vitro GBM models, where almost
100% of cells are cycling29. Finally, in agreement with previous
literature on patient samples, cells with high proneural scores also
score highly on stemness as is the case for our TP53−/−;
PDGFRAΔ8–9 iHGG samples (Supplementary Fig. 11c–e)29. In
conclusion, our results highlight the robustness of our iHGG
models, for both spheres and tumors, in recapitulating hallmarks
of patient GBM samples as is the case for cellular inter- and intra-
tumor heterogeneity, subtype signatures and cycling and stem-
ness scores.
Distinct iHGGs present different patterns of tumor evolution.
It is also apparent from the UMAP plots that the transcriptomic
signature of primary spheres evolves as they are passaged through
mice, excised, and cultured in vitro. In fact, by analyzing sepa-
rately the transition of each genotype model from primary to
secondary spheres, we gain insights into the biology of the tumors
as well as the role that in vivo passaging plays. We performed
unsupervised Louvain clustering of PTEN−/−;NF1−/− iHGG
primary and secondary spheres (Fig. 5a) and, in parallel,
TP53−/−;PDGFRAΔ8–9 iHGG primary and secondary spheres
(Fig. 5b) and found 8 and 15 distinct clusters, respectively. In
both cases primary spheres are represented, almost exclusively, by
unique clusters not found in any secondary spheres. Remarkably,
all three PTEN−/−;NF1−/− iHGG secondary spheres are found in
very similar proportions in the remaining clusters. In stark con-
trast, each of the TP53−/−;PDGFRAΔ8–9 iHGG secondary spheres
show unique cluster makeups.
Moreover, when the differentially expressed genes of each
cluster are subjected to gene ontology (GO) analysis, different
patterns emerge for each iHGG model. PTEN−/−;NF1−/− iHGG
spheres are subdivided in two broad categories, namely cell cycle
or cell motility and extra- and intra-cellular fiber reorganization,
with several cluster sharing a variety of GO terms (Fig. 5c). In
fact, both categories appear to be exacerbated following tumor
formation in mice as shown by the increase in the number of GO
terms associated with each secondary sphere cluster. This increase
in cell motility terms supports our observation regarding more
prominent diffuse invasion of PTEN−/−;NF1−/− iHGG compared
with TP53−/−;PDGFRAΔ8–9 iHGG (Supplementary Fig. 12). In
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contrast, in addition to cell cycle associated GO terms, TP53−/−;
PDGFRAΔ8–9 iHGG spheres are represented by diverse GO terms,
many of which are unique to each secondary sphere, including
glial cell differentiation, response to hypoxia, embryonic morpho-
genesis and, similarly to PTEN−/−;NF1−/− iHGG spheres, cell
motility associated terms (Fig. 5d). Likewise, the mesenchymal
signature of PTEN−/−;NF1−/− iHGG spheres is homogenous
across most clusters, whereas proneural scores are heterogeneous
in nature (Supplementary Figs. 13 and 14). Overall, even though
both iHGG models show transcriptional drift from primary to
secondary spheres, TP53−/−;PDGFRAΔ8–9 iHGGs appear to show
a less unidirectional path with increased heterogeneity.
We previously reported that extrachromosomal DNA (ecDNA)
is prevalent in many cancer types, especially in GBM, and that
ecDNA is associated with resistance to drug treatment and rapid
evolution of tumor heterogeneity30,31. To determine if our iGBM
models recapitulated the generation of ecDNA, we first investi-
gated if the original input NPCs possessed karyotype abnormal-
ities or traces of ecDNA. Based on DAPI staining of metaphase
spreads and digital karyotyping, PTEN−/−;NF1−/− iHGG cells
were karyotypically normal (Fig. 6a). In sharp contrast, metaphase
spreads of cells obtained from TP53−/−;PDGFRAΔ8–9 iHGGs
showed small DAPI-stained dots adjacent to chromosomes,
suggestive of ecDNA (Fig. 6b), consistent with our previous
findings in GBM tumor samples31. Furthermore, double minute-
like structures became more apparent in the secondary tumors
obtained by re-engraftment of the primary spheres (Fig. 6c), and
were replication competent as indicated by incorporation of EdU
(Fig. 6d). The TP53−/−;PDGFRAΔ8–9 iHGGs also presented
striking numerical and structural chromosome alterations (Fig. 6e).
This supports a clonally unstable nature of the TP53−/−;
PDGFRAΔ8–9 model, where genomic instability or ecDNA could
be driving dynamic accelerated clonal evolution31,32.
iHGGs confirm features characteristic of patient samples. We
also applied unsupervised Louvain clustering of PTEN−/−;
NF1−/− iHGG secondary tumors (Fig. 7a) and, in parallel,
TP53−/−;PDGFRAΔ8–9 iHGG secondary tumors (Fig. 7b) to
further compare inter- and intra-tumor variability of our iHGG
tumor models and found 7 and 8 distinct clusters, respectively.
Each one of the clusters is represented by a unique set of
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differentially expressed genes which, if stratified by sample, show
no clear patterns, as would be expected when intra-tumor het-
erogeneity is present at the single-cell level (Supplementary
Fig. 15). Furthermore, PTEN−/−;NF1−/− iHGG secondary tumors
appear more homogenous than their TP53−/−;PDGFRAΔ8–9
counterparts as each one of the triplicates is represented in all
clusters. On the contrary, TP53−/−;PDGFRAΔ8–9 iHGG secondary
tumors show clusters containing cells from all samples but also
several clusters comprised of only two or almost exclusively one
sample, indicating increased inter-tumor variability.
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Significantly, when GBMmolecular subtypes of each cluster are
inspected, PTEN−/−;NF1−/− samples show, for the most part, a
homogenous mesenchymal signature, with the exception of two
clusters (‘E’ and ‘G’) (Fig. 7c). In stark contrast, subtype
signatures of each cluster derived from TP53−/−;PDGFRAΔ8–9
tumors show unique combinations, with three clusters accounting
for the majority of the proneural signature and smaller
contributions by the remaining clusters with the exception of
cluster ‘O’ which has a clear mesenchymal signature (Fig. 7d).
Notably, for both models, intra-tumor heterogeneity is also
observed as each cluster presents signatures of different molecular
subtypes, a hallmark of GBM patient samples29. Finally, some
TP53−/−;PDGFRAΔ8–9 tumor clusters also score higher for
stemness in comparison to PTEN−/−;NF1−/− clusters; while
both models show a heterogenous composition of cycling and
noncycling cells (Fig. 7e, f). In conclusion, our isogenic models
faithfully recapitulate HGG pathobiology, including inter- and
intra-tumor heterogeneity, differential drug sensitivity, ecDNA
amplifications, and rapid clonal evolution. Variations of this
tumor avatar platform can be applied to different types of cancers
and will allow, amongst other things, the study of clonal
evolution, longitudinal assessment in vitro and in vivo, and
genotype-based therapeutic vulnerabilities deciphered in an
isogenic background.
Discussion
We generated isogenic iHGG models from hiPSCs by introducing
different combinations of genetic alterations characteristic of this
disease. These models both recapitulated pathological features of
HGG, but at the same time, displayed distinct mutation-
dependent variation in histological morphology, gene expres-
sion, and ploidy. Some of our findings were consistent with
previous mouse models. For example, NF1-deleted tumors and
PDGF-driven tumors showed features of mesenchymal and
proneural subtype, respectively in mouse models33–35, where the
former tumors were resistant to TMZ while the latter tumors
were sensitive to the drug33. Such consistency among our models,
patient samples, and previous models suggests the key roles of
small numbers of driver mutations in determining tumor phe-
notypes. The heterogeneity presented in our models is an
essential feature for the proper modeling of GBM as this pro-
minent characteristic is a confounding aspect making these
tumors difficult to treat. Although there have been several models
generated from pluripotent cells and genome editing technologies
to date15, our iHGG models are distinct in the way that they
present exact pathognomonic features of GBM, and reproduce
the heterogeneity of the disease from isogenic cells. These
approaches have been applied for models of other brain tumors
such as medulloblastoma36. One limitation in our approach is
that genome engineering was performed in hiPSCs, an irrelevant
cell of origin for GBM. However, the fact that tumor models
derived from appropriately differentiated NPCs from edited
hiPSCs recapitulate GBM pathobiology suggests that our
platform has potential for broader cancer modeling using various
cell lineage differentiation protocols applied to hiPSCs. Further-
more, recent development of 3D in vitro brain tumor models
using cerebral organoid suggests that several different combina-
tions of oncogenic mutations give rise to expanding tumor-like
components within organoids, which would approximate in vivo
conditions better than conventional cell culture conditions37.
Such applications of advanced differentiation technology of
pluripotent stem cells and genome engineering enabling intro-
duction of genetic alterations actually observed in patient sam-
ples, could further develop the next generation of cancer models.
A combination of EGFR activation and inactivation of Ink4a/
Arf, which are common co-occurring genetic alterations observed
in high-grade gliomas, has been shown to play a role in ded-
ifferentiation of astrocytes through the process of gliomagen-
esis38. How the genetic alterations we engineered in NPCs
contribute to the formation of iHGGs is to be further studied, and
presents an ideal platform to investigate mechanisms promoting
transformation guided by cell lineage. Also, how the NPCs with
GBM associated mutations, which prior to orthotopic engraft-
ment do not show GBM subtype specific transcriptome sig-
natures, present such signatures through the process of in vivo
transformation, is to be further investigated.
Once xenograft tumors were obtained with our proneural and
mesenchymal iHGG models, cells from these tumors maintained
tumorigenicity and formed secondary tumors in vivo resembling
the original tumors, as also seen in PDX models39. Owing to this
characteristic, the iHGG cells can be passaged and maintained as
cell lines once tumors are obtained. Further, as shown here, it is
quite feasible to introduce different combinations of genetic
alterations in hiPSCs, and such different edits result in divergent
phenotypes. Thus, by expanding our gene-editing spectrum, we
expect that these models would enable us to evaluate the influence
of select driver genetic alterations found in different cancer types,
which is less feasible with PDX models due to numerous acquired
passenger mutations and genetic backgrounds that are highly
variable sample to sample.
Another striking finding in our iHGG models was aneuploidy
accompanied by ecDNA, observed in TP53−/−;PDGFRAΔ8–9
tumors. In our previous analyses, ecDNA was observed in more
than 80% of PDX cell lines derived from GBM31, suggesting that
ecDNA formation is a fundamental feature in the pathogenesis of
GBM. Interestingly, a mouse model with a combination of
CDKN2A−/− and a PDGFRA point mutation showed brain
tumors with double minute chromosomes or ecDNA40, while
another CDKN2A−/− mouse model that generated brain tumors
after irradiation similarly had ecDNA41. Using human intestinal
stem cells that were edited for the most commonly mutated
colorectal cancer genes (APC, TP53, KRAS and SMAD4), exten-
sive aneuploidy occurred and these quadruple mutant cells grew
as tumors in immunocompromised mice with features of invasive
carcinoma12. Together with our results, these previous models
suggest alterations in TP53 or CDKN2A, which are commonly
affected in GBM as well as other cancer types, play an essential
role in the genesis of chromosomal instability that results in
aneuploidy or ecDNA formation. In summary, we propose a
modeling system for HGG by introducing different combinations
of essential genetic alterations in hiPSCs, which result in tumor
avatars faithfully recapitulating histology, gene expression sig-
natures, and cytogenetic features of HGG. As these avatars are
faithfully expressing gene expression signatures characteristic of
GBMs, we expect that these models will be a useful platform to
study cancer biology based on genetic drivers, cell of origin
defined by the differentiation program of genome-edited iPSCs,
and possible other parameters such as xenograft location and
gender differences.
Methods
Cell culture. Experiments using human pluripotent stem cells were conducted
under the regulations of the UCSD Human Research Protections Program, project
number 151330ZX. Human iPS cells, CV-iPS-B cells were obtained from Dr
Lawrence S. B. Goldstein42. CV-iPS-B cells were cultured on plates coated with
Matrigel hESC-Qualified Matrix (Corning) in mTeSR1 media (Stemcell Technol-
ogies). NPCs were cultured on matrigel-coated plates in NPC maintenance media
containing DMEM/F12 with GlutaMAX (Thermo Fisher Scientific), 1 × N-2 sup-
plement (Thermo Fisher Scientific), 1 × B-27 supplement (Thermo Fisher Scien-
tific), 50 mM ascorbic acid (Tocris), 3 µM CHIR99021 (Tocris) and 0.5 µM
purmorphamine (Tocris). Sphere cells were cultured in suspension in DMEM/F12
with GlutaMAX (Thermo Fisher Scientific) with 1 × B-27 supplement, 20 ng/ml
EGF (Stemcell Technologies) and 20 ng/ml bFGF (Stemcell Technologies).
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Generation of genetically engineered hiPSC clones. A plasmid, pSpCas9(BB)-
2A-GFP or px458, which expresses Cas9-T2A-GFP and sgRNA43, was purchased
from Addgene (Plasmid #48138). The designated sgRNA sequences for each of the
targeted genes were cloned into px458 using combinations of top and bottom
oligonucleotides listed below.
PTEN-intron 4-top: 5′-CACCGGAATTTACGCTATACGGAC-3′,
PTEN-intron 4-bottom: 5′-AAACGTCCGTATAGCGTAAATTCC-3′,
PTEN-intron 5-top: 5′-CACCGAACAAGATCTGAAGCTCTAC-3′,
PTEN-intron 5-bottom: 5′-AAACGTAGAGCTTCAGATCTTGTTC-3′,
TP53-intron 1-top: 5′-CACCGGGTTGGAAGTGTCTCATGC-3′,
TP53-intron 1-bottom: 5′-AAACGCATGAGACACTTCCAACCC-3′,
TP53-intron 6-top: 5′-CACCGCATCTCATGGGGTTATAGGG-3′,
TP53-intron 6-bottom: 5′-AAACCCCTATAACCCCATGAGATGC-3′,
NF1-intron 31-top: 5′-CACCGATAGCACTCTTCCCGAGCTA-3′,
NF1-intron 31-bottom: 5′-AAACTAGCTCGGGAAGAGTGCTATC-3′,
NF1-intron 33-top: 5′-CACCGCTTTGGGGAGGTCTTTCGTC-3′,
NF1-intron 33-bottom: 5′-AAACGACGAAAGACCTCCCCAAAGC-3′,
PDGFRA-intron 7-top: 5′-CACCGATTTGTATGTAGCGGTCTGC-3′,
PDGFRA-intron 7-bottom: 5′-AAACGCAGACCGCTACATACAAATC-3′,
PDGFRA-intron 9-top: 5′-CACCGCCACGGGAACACTCTAAGA-3′,
PDGFRA-intron 9-bottom: 5′-AAACTCTTAGAGTGTTCCCGTGGC-3′.
Each of top and bottom oligonucleotides were phosphorylated and annealed by
incubating 10 µM each of oligonucleotides, 1 × T4 DNA ligase buffer (New England
Biolabs), 5U T4 polynucleotide kinase (New England Biolabs) at 37 °C for 30 min,
95 °C for 5 min and by cooling down to 25 °C at 0.1 °C/s using a thermocycler.
Annealed oligonucleotides were cloned into px458 by incubating 25 ng px458, 1 μM
annealed oligonucleotides, 1× CutSmart buffer (New England Biolabs), 1 mM ATP
(New England Biolabs), 10U BBSI-HF (New England Biolabs) and 200U T4 ligase
(New England Biolabs) at 37 °C for 5 minutes, 23 °C for 5 min for 30 cycles. Correct
cloning of each sgRNA sequence was confirmed by Sanger sequencing using
U6 sequencing primer: 5′-GATACAAGGCTGTTAGAGAGATAATT-3′.
Human iPSCs were cultured in 10 µM Y-27632 RHO/ROCK pathway inhibitor
for 2 h before dissociation. The cells were dissociated to single cells using Accutase
(Innovative Cell Technologies). The dissociated hiPSCs (1 × 106 cells) were
resuspended in 100 µl of supplemented solution of the Human Stem Cell
Nucleofector Kit 1 (Lonza) containing 8 µg total of a combination of px458
plasmids targeting each gene and electroporated using B-016 program of
Nucleofector 2b (Lonza). Electroporated hiPSCs were cultured on matrigel-coated
plates in mTeSR1 for 48 h. GFP-positive cells were then sorted by flow cytometer
(SH800, SONY) and 1–2 × 104 sorted cells were plated on a 10-cm matrigel-coated
plate in mTeSR1. Isolated colonies were manually picked and plated in duplicated
matrigel-coated 96-well plates.
The hiPSCs clones on one of the duplicated 96-well plates were lysed using
QuickExtract DNA Extraction Solution (Epicenter) and genotyping PCR was
performed using Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher
Scientific) in 10-μl reaction volume containing 0.2 μM of each primer with the
following reaction conditions: 94 °C for 2 min, 40 cycles of 94 °C for 15 s, 55 °C for
30 s, and 68 °C for 4 min. The PCR amplicons were visualized in agarose gels
(Supplementary Fig. 1). Primers used for the genotyping PCR are listed below.
PTEN-i4-f: 5′-GAGTCCTGACGAAATGTCCATG-3′,
PTEN-i5-r: 5′-CCTGTT TTCCAGGGACTGAG-3′,
NF1-i31-f: 5′-ACTCTGGAAAGGGATGGGAG-3′,
NF1-i33-r: 5′-CCGGCTTCAGCTTCAAAGTAG-3′,
TP53-i1-f: 5′-CCGATCACCTGAAGTAAGGAG-3′,
TP53-i6-r: 5′-CCTTAGCCTCTGTAAGCTTCAG-3′,
PDGFRA-i7-f: 5′-TGTACTCCTGTCCCCAGCTG-3′,
PDGFRA-i9-r: 5′-TCCTGAGAGTCATGGCAATG-3′.
Total RNA was extracted from the edited hiPSCs using RNeasy Plus Mini Kit
(Qiagen) and was reverse transcribed using RNA to cDNA EcoDry Premix
(Clontech) according to the manufacturer’s instruction. Triplicate qPCR reactions
containing cDNA obtained from 10 ng equivalent RNA were run on a CFX96 Real
Time System (Bio-Rad) to confirm designated targeting of the genes with the
following reaction conditions: 95 °C for 5 min, 40 cycles of 95 °C for 15 s, 56 °C for
30 s. Primer pairs were designed to span the deleted regions of each target gene.
The data were normalized to GAPDH and the relative transcript levels were
determined using 2-ΔCt formula. Primers used for the RT-qPCR are listed below.
GAPDH-RT-f: 5′-AATTTGGCTACAGCAACAGGGTGG-3′,
GAPDH-RT-r: 5′-TTGATGGTACATGACAAGGTGCGG-3′,
PTEN-RT-f: 5′-CGAACTGGTGTAATGATATGT-3′,
PTEN-RT-r: 5′-CATGAACTTGTCTTCCCGT-3′,
NF1-RT-f: 5′-GCCACCACCTAGAATCGAAAG-3′,
NF1-RT-r: 5′-AGCAAGCACATTGCCGTCAC-3′,
TP53-RT-f: 5′-CCAAGTCTGTGACTTGCACG-3′,
TP53-RT-r: 5′-GTGGAATCAACCCACAGCTG-3′,
PDGFRAΔ8–9-RT-f: 5′-GATGTGGAAAAGATTCAGGAAATAAGATG-3′,
PDGFRAwt-RT-f: 5′-CGCCGCTTCCTGATATTGAG-3′,
PDGFRA-RT-r: 5′-CTCCACGGTACTCCTGTCTC-3′.
The qPCR products were visualized by agarose gel electrophoresis.
Differentiation of hiPSCs to neural progenitor cells. Generation of small
molecule neural progenitor cells (smNPCs) from iPSCs was adapted from a
previous study 21. In detail, human iPSCs at 70–80% confluency were dissociated
using accutase (Innovative Cell Technologies) and resuspended at 1 × 106 cells/ml
in N2B27 medium (DMEM/F12 with GlutaMAX (Thermo Fisher Scientific),
1 × N-2 supplement (Thermo Fisher Scientific), 1 × B-27 supplement (Thermo
Fisher Scientific), 150 mM ascorbic acid (Tocris), and 1% Penicillin/Streptomycin)
supplemented with 1 µM Dorsomorphin (Tocris), 10 µM SB431542 (Tocris), 3 µM
CHIR99021, 0.5 µM Purmorphamine and 5 mM Y-26732 (Stemcell Technologies).
Three million cells were transferred into one well of an uncoated six-well tissue
culture plate and incubated at 37 °C, 5% CO2 on a shaker at 90 rpm. Uniform small
EBs formed within 24 h and increased in size over the following days. After 48 h, a
full media change was performed with N2B27 medium supplemented with Dor-
somorphin, SB431542, CHIR99021, and Purmorphamine. At this time, about 2/3
of EBs were either discarded or EBs were split across three wells of a six-well plate
to reduce the high cell density required initially to ensure uniform formation of
embryoid bodies. On days 3–5, half media change was performed with fresh N2B27
media supplemented with Dorsomorphin, SB431542, CHIR99021, and Purmor-
phamine. On day 6, Dorsomorphin and SB431542 were withdrawn and a full
media change with smNPC media (N2B27 media supplemented with 3 µM
CHIR99021 and 0.5 µM Purmorphamine) was performed. At this stage, neuroe-
pithelial folds were clearly visible in all EBs. On day 8, EBs were triturated by
pipetting 10–15 times with a P1000 pipette and plated onto matrigel-coated 10 cm
plates. After 3–4 days, attached EB fragments and outgrown cells were dissociated
to single cells with accutase (Innovative Cell Technologies) and split at a 1:6–1:8
ratio onto matrigel-coated plates. After the first passage, cells were passaged at a
1:10–1:15 ratio every 3–6 days. For the first few passages, large flat non-smNPCs
could be observed between smNPC colonies, but progressively disappeared no later
than passages 3–6 in almost all cell lines. Total RNA was extracted from the
differentiated smNPCs using the RNeasy Plus Mini Kit and was reverse transcribed
using RNA to cDNA EcoDry Premix according to the manufacturer’s instruction.
Triplicate qPCR reactions containing cDNA obtained from 10 ng equivalent RNA
were run on a CFX96 Real Time System to confirm NPC differentiation with the
following reaction conditions: 95 °C for 5 min, 40 cycles of 95 °C for 15 s, 56 °C for
30 s. The data were normalized to GAPDH and the relative transcript levels were
determined using 2-ΔCt formula. Primers used for the RT-qPCR are listed below.
Nanog-RT-f: 5′-GAAATACCTCAGCCTCCAGC-3′,
Nanog-RT-r: 5′-GCGTCACACCATTGCTATTC-3′,
Oct4-RT-f: 5′-AGAACATGTGTAAGCTGCGG-3′,
Oct4-RT-r: 5′-GTTGCCTCTCACTCGGTTC-3′,
Nestin-RT-f: 5′-GGTCTCTTTTCTCTTCCGTCC-3′,
Nestin-RT-r: 5′-CTCCCACATCTGAAACGACTC-3′,
Pax6-RT-f: 5′-GCCCTCACAAACACCTACAG-3′,
Pax6-RT-r: 5′-TCATAACTCCGCCCATTCAC-3′,
Sox1-RT-f: 5′-CAGCAGTGTCGCTCCAATCA-3′,
Sox1-RT-r: 5′-GCCAAGCACCGAATTCACAG-3′.
Spontaneous differentiation of NPCs was performed by maintaining NPCs on
matrigel-coated plates in DMEM supplemented with 10% FBS for a week.
Intracranial tumor formation. Animal research experiments were approved by the
UCSD Animal Care Program, protocol number S00192M, and were performed
under its regulations. Wildtype and edited smNPCs were dissociated using accutase
(Innovative Cell Technologies), washed with PBS, and resuspended at 1 × 106 cells
in 2 µL PBS supplemented with 0.1% BSA per animal. Resuspended cells were kept
on ice and were inoculated into the striatum of 4–6 week-old female Nod scid mice
(Charles River Laboratory) by stereotactic injections (1.0 mm anterior and 2.0 mm
right to the bregma, and 3 mm deep from the inner plate of the skull). Wildtype
hiPSCs were injected as a control as well.
Immunohistochemistry. Paraffin-embedded tissue blocks were sectioned using the
UCSD Moore’s Cancer Center Pathology Core and the Center for Advanced
Laboratory Medicine (UCSD). Tissue sections were stained with antibodies to
GFAP (1:6000) from Dako (Cat #Z0334), Olig2 (1:300) from EMD Millipore (Cat
#Ab6910; Lot #3018858) Ki-67 (pre-diluted47) from Ventana Medical Systems
(Cat #760-4286) and NM95 (1:300) from Abcam (Cat # ab190710). Slides were
stained on a Ventana Discovery Ultra. Antigen retrieval was performed using CC1
for 24–40 min at 95 °C (or protease 2 for 12 min for GFAP). The primary anti-
bodies were incubated on the sections for 32 min at 37 °C. Primary antibodies were
visualized using the OmniMap system (HRP-labeled goat anti-mouse or rabbit;
Ventana Medical systems) and used DAB as a chromagen followed by hematoxylin
as a counterstain. Slides were rinsed, dehydrated through alcohol and xylene and
coverslipped immunohistochemical stains for GFAP and Olig2 were graded as
follows: 0 (no cells stained), 1+ (<5% tumor cells stained), 2+ (5–50% cells
stained), and 3+ (>50% cells stained). Ki-67 positivity was manually counted on six
different high power fields for each model.
Sphere cell culture of iHGG. Tumors were excised from mouse brains and cut in
small pieces using a scalpel, and then incubated in 3.6 ml of Hank’s Balanced Salt
Solution (HBSS, Sigma) with 0.4 ml of 10× Trypsin solution (Sigma) at 37 °C for
20 min. After incubation, 200 μl of 10 mg/ml DNaseI stock solution (Sigma) was
added and incubated for 60 s, and then 6 ml of HBSS was added to neutralize
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Trypsin and DNaseI. Tumor tissue was resuspended by pipetting up and down
several times through a glass Pasteur pipette. Dissociated tissue was filtered
through a strainer and was spun down by centrifugation at 400 × g for 3 min. Cells
were resuspended in 1 ml of PBS and 9 ml of ACK lysing buffer (Invitrogen) and
were incubated at 37 °C for 10 min to remove red blood cells. Approximately 1 ×
106 cells were resuspended in 100 µl of MACS/BSA buffer (Miltenyi Biotec) and
were incubated with 2 µl of Fc blocking solution (BioLegend) for 5 min on ice.
After blocking, 5 µl of PE-conjugated antihuman HLA-A,B,C antibody (BioLegend)
was added and cells were incubated for 15 min on ice. Stained cells were washed
twice with 500 µl of MACS/BSA buffer. PE-positive cells were then sorted using a
flow cytometer (SH800, SONY). Sorted human iHGG cells were maintained in
DMEM/F12 with GlutaMAX (Thermo Fisher Scientific) with 1 × B-27 supplement
(Thermo Fisher Scientific), 20 ng/ml EGF (Stemcell Technologies) and 20 ng/ml
bFGF (Stemcell Technologies).
Extreme limiting dilution assay. Extreme limiting dilution assay was performed
based on a previous literature24. In detail, NPCs and iHGG spheres were dis-
sociated into single cells using accutase (Innovative Cell Technologies) and 1, 5, 10,
20, 50, and 100 cells/well were plated in 96-well plates with five replicates for each
experimental condition. The total number of spheres, per well and per treatment,
were quantified after 14 days in culture. Data were analyzed by extreme limiting
dilution analysis (http://bioinf.wehi.edu.au/software/elda/).
Secondary tumor models and temozolomide treatment. Primary iHGG spheres
were dissociated using accutase (Innovative Cell Technologies), washed with PBS,
and resuspended at 2.5 × 105 cells in 2 µl PBS supplemented with 0.1% BSA per
animal. Resuspended cells were kept on ice and were inoculated as indicated above.
Treatment of the mice started 7 days after inoculation of the iHGG cells by
intraperitoneal injection of either vehicle (DMSO) or 50 mg/kg of TMZ (Sell-
eckchem). The mice were treated once daily for the first 3 days followed by 2-day
drug holidays, and then once daily for 2 days again followed by 2-day drug holidays
and another set of 2-day once daily treatment. This set of treatment was repeated
every 4 weeks and percentage of surviving mice over time was recorded. RT-qPCR
to evaluate MGMT expression was run on a CFX96 real time system to confirm
differentiation to NPCs with the following reaction conditions: 95 °C for 5 min,
40 cycles of 95 °C for 15 s, 56 °C for 30 s. The data were normalized to GAPDH and
the relative transcript levels were determined using 2-ΔCt formula. Primers used
for the RT-qPCR are listed below.
MGMT-RT-f: 5′-GCTGAATGCCTATTTCCACCA-3′,
MGMT-RT-r: 5′-CACAACCTTCAGCAGCTTCCA-3′,
Cytogenetics. Metaphase cells were obtained by treating cells with Karyomax
(Gibco) at a final concentration of 0.1 µg/ml for 1–3 h. Cells were collected, washed
in PBS, and resuspended in 0.075 M KCl for 15–30 min. Carnoys fixative
(3:1 methanol/glacial acetic acid) was added dropwise to stop the reaction.
Cells were washed an additional three times with Carnoys fixative, before being
dropped onto humidified glass slides for metaphase cell preparations. DAPI was
added to the slides. Images were captured with an Olympus FV1000 confocal
microscope.
Spectral karyotyping analysis was performed at Applied Spectral Imaging.
Genomic DNA extracted from NPCs and iHGG cells using DNeasy blood and
tissue kit (Qiagen) was analyzed by digital karyotyping using Illumina HiScan
system (Illumina).
To detect DNA replication, cells were labeled with EdU and detected using the
Click-iT Plus EdU Alexa Fluor 594 imaging kit (Invitrogen). Briefly, cells were
pulse labeled with EdU (10 µM) for 1 h, then allowed to progress to metaphase for
12 h. KaryoMax (0.1 µg/ml) was added for 3 h to arrest cells in metaphase. The cells
were then collected and metaphase spreads were prepared31. Cells in metaphase
were dropped onto a glass slide, and EdU was detected by applying the Click-iT
reaction cocktail directly onto the slides for 20 min at room temperature. Slides
were then washed with 2× SSC and mounted with antifade mounting medium
containing DAPI. Cells in metaphase were imaged using an Olympus BX43
fluorescent microscope equipped with a QIClick camera.
RNA sequencing. Total RNA was assessed for quality using an Agilent Tapesta-
tion, and all samples had RNA Integrity Numbers above 9.0. RNA libraries
were generated using llumina’s TruSeq Stranded mRNA Sample Prep Kit (Illu-
mina) following manufacturer’s instructions. RNA-seq reads were aligned to the
human genome (hg19) with STAR 2.4.0 h (outFilterMultimapNmax 20, out-
FilterMismatchNmax 999, outFilterMismatchNoverLmax 0.04, out-
FilterIntronMotifs RemoveNoncanonicalUnannotated, outSJfilterOverhangMin 6 6
6 6, seedSearchStartLmax 20, alignSJDBoverhangMin 1) using a gene database
constructed from Gencode v1944,45. Reads that overlap with exon coordinates were
counted using HTSeqcount (-s reverse -a 0 -t exon -i gene_id -m union)46,47. Raw
read counts were processed with DESeq248 and only genes with mean read count
over 20 were considered for the analysis. Raw read counts were transformed using
the variance stabilizing transformation function included in DESeq249. Mean and
standard deviation of normalized expression were calculated for each gene and Z-
scores were determined by subtracting the mean from each expression value and
dividing by the standard deviation.
scRNA-seq and analysis. For the scRNA-seq of secondary tumor cells, the tumors
were dissected from mouse brains, cut into small pieces, and then incubated in
HBSS (Sigma) containing 1× trypsin (Sigma) at 37 °C for 20 min, followed by
mechanical dissociation using glass pipettes to obtain single cells. Cultured sphere
cells were dissociated using accutase (Innovative Cell Technologies). Single cells
were processed through the Chromium Single-Cell Gene Expression Solution using
the Chromium Single Cell 3′ Gel Bead, Chip and Library Kits v2 (10× Genomics)
as per the manufacturer’s protocol. In brief, single cells were resuspended in 0.04%
BSA in PBS. Ten thousand total cells were added to each channel with an average
recovery of 3040 cells. The cells were then partitioned into Gel Beads in Emulsion
in the Chromium instrument, where cell lysis and barcoded reverse transcription of
RNA occurred, followed by amplification, shearing and 5′ adapter and sample
index attachment. Agilent High Sensitivity D5000 ScreenTape Assay (Aglient
Technologies) was performed for QC of the libraries. Libraries were sequenced on
an Illumina NovaSeq. De-multiplexing, alignment to the hg19 transcriptome and
unique molecular identifier-collapsing were performed using the Cellranger toolkit
(version 2.0.1) provided by 10× Genomics. A total of 42,558 cells with ~53,000
mapped reads per cell were processed. Analysis of output digital gene expression
matrices was performed using the Scanpy v1.3.3 package50. Matrices for all samples
were concatenated and all genes that were not detected in at least 20 single cells
were discarded, leaving 20,521 genes for further analyses. Cells with fewer than 600
or more than 8000 expressed genes as well as cells with more than 80,000 tran-
scripts or 0.1% mitochondrial expressed genes were removed from the analysis. For
the different sample subset combination analysis filtering steps were the same with
the exception of specific gene and transcript thresholds for which cells were
removed: PTEN−/−;NF1−/− spheres (fewer than 600 or more than 7000 expressed
genes and more than 50,000 transcripts), PTEN−/−;NF1−/− tumors (fewer than
600 or more than 8000 expressed genes and more than 80,000 transcripts),
TP53−/−;PDGFRAΔ8–9 spheres (fewer than 600 or more than 7000 expressed genes
and more than 70,000 transcripts), TP53−/−;PDGFRAΔ8–9 tumors (fewer than 600
or more than 6000 expressed genes and more than 40,000). Data were log nor-
malized and scaled to 10,000 transcripts per cell. Top 4000 variable genes were
identified with the filter_genes_dispersion function, flavor= ʻcell_ranger’. PCA
was carried out, and the top 25 principal components were retained (21, 20, 23, and
24 for PTEN−/−;NF1−/− spheres, PTEN−/−;NF1−/− tumors, TP53−/−;
PDGFRAΔ8–9 spheres and TP53−/−;PDGFRAΔ8–9 tumors, respectively). With these
principal components, neighborhood graphs were computed with 20 neighbors and
standard parameters with the pp.neighbors function. Louvain clusters were com-
puted with the tl.louvain function and standard parameters (and 0.4, 0.4, 0.7 and
0.4 resolution for PTEN−/−;NF1−/− spheres, PTEN−/−;NF1−/− tumors, TP53−/−;
PDGFRAΔ8–9 spheres and TP53−/−;PDGFRAΔ8–9 tumors, respectively). Single cell
and mean expression per sample heatmaps were generated with the pl.heatmap and
pl.matrixplot functions, respectively. Single-cell scores for TCGA molecular sub-
types as well as stemness and cell cycle genes (see Supplementary Data 1) were
computed with the tl.score_genes and tl.score_genes_cell_cycle functions, respec-
tively. Differentially expressed genes were determined for each set of Louvain
clusters with the tl.rank_gene_groups function (method= ʻwilcoxon’). For GO
analysis of primary and secondary spheres, differentially expressed genes of each
Louvain cluster with log2fold over 0.5 and p-adjusted values under 0.05 were used
as inputs (see Supplementary Data 2) on Metascape 51 (multiple gene list option
and standard parameters), using all expressed genes in the 14 samples as back-
ground. Enrichment results are summarized in Supplementary Data 3.
Statistical analyses. All statistical analyses were performed using GraphPad Prism
6 software. Data are representative of results obtained in at least three independent
experiments. Data sets were analyzed by unpaired t-test to determine significance
(p < 0.05). Kaplan–Meier curves and comparison of survival were analyzed using
Log-rank (Mantel–Cox) test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Single-cell RNA sequencing and bulk RNA sequencing data have been deposited in the
Gene Expression Omnibus database under GSE133479 [https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE133479] and GSE133509 [https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE133509] respectively. All the other data supporting the
findings of this study are available within the article and its supplementary information
files and from the corresponding author upon reasonable request. A reporting summary
for this article is available as a Supplementary Information file.
Received: 24 October 2019; Accepted: 20 December 2019;
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14312-1
12 NATURE COMMUNICATIONS |          (2020) 11:550 | https://doi.org/10.1038/s41467-020-14312-1 | www.nature.com/naturecommunications
References
1. Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Glioblastoma: from
molecular pathology to targeted treatment. Annu. Rev. Pathol. 9, 1–25 (2014).
2. Stylli, S. S., Luwor, R. B., Ware, T. M., Tan, F. & Kaye, A. H. Mouse models of
glioma. J. Clin. Neurosci. 22, 619–626 (2015).
3. Chow, L. M. et al. Cooperativity within and among Pten, p53, and Rb
pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19,
305–316 (2011).
4. Lenting, K., Verhaak, R., Ter Laan, M., Wesseling, P. & Leenders, W. Glioma:
experimental models and reality. Acta Neuropathol. 133, 263–282 (2017).
5. Rich, J. N. et al. A genetically tractable model of human glioma formation.
Cancer Res. 61, 3556–3560 (2001).
6. Sonoda, Y. et al. Formation of intracranial tumors by genetically modified
human astrocytes defines four pathways critical in the development of human
anaplastic astrocytoma. Cancer Res. 61, 4956–4960 (2001).
7. Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics
for Glioblastoma. Cell 178, 835–849 (2019).
8. Wang, Q. et al. Tumor evolution of glioma-intrinsic gene expression subtypes
associates with immunological changes in the microenvironment. Cancer Cell
32, 42–56 (2017).
9. Patrizii, M., Bartucci, M., Pine, S. R. & Sabaawy, H. E. Utility of glioblastoma
patient-derived orthotopic xenografts in drug discovery and personalized
therapy. Front. Oncol. 8, 23 (2018).
10. Hockemeyer, D. & Jaenisch, R. Induced pluripotent stem cells meet genome
editing. Cell Stem Cell 18, 573–586 (2016).
11. Bressan, R. B. et al. Efficient CRISPR/Cas9-assisted gene targeting enables
rapid and precise genetic manipulation of mammalian neural stem cells.
Development 144, 635–648 (2017).
12. Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem
cells. Nature 521, 43–47 (2015).
13. Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated
engineering of human intestinal organoids. Nat. Med. 21, 256–262 (2015).
14. Tuveson, D. & Clevers, H. Cancer modeling meets human organoid
technology. Science 364, 952–955 (2019).
15. Duan, S. et al. PTEN deficiency reprogrammes human neural stem cells
towards a glioblastoma stem cell-like phenotype. Nat. Commun. 6, 10068,
https://doi.org/10.1038/ncomms10068 (2015).
16. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems.
Science 339, 819–823 (2013).
17. Jinek, M. et al. RNA-programmed genome editing in human cells. Elife 2,
e00471, https://doi.org/10.7554/eLife.00471 (2013).
18. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell 17, 98–110 (2010).
19. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell
155, 462–477 (2013).
20. Ozawa, T. et al. PDGFRA gene rearrangements are frequent genetic
events in PDGFRA-amplified glioblastomas. Genes Dev. 24, 2205–2218
(2010).
21. Reinhardt, P. et al. Derivation and expansion using only small molecules of
human neural progenitors for neurodegenerative disease modeling. PLoS One
8, e59252, https://doi.org/10.1371/journal.pone.0059252 (2013).
22. Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide
precision medicine. Cancer Discov. 7, 462–477 (2017).
23. Akhavan, D. et al. De-repression of PDGFRbeta transcription promotes
acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma
patients. Cancer Discov. 3, 534–547 (2013).
24. Hu, Y. & Smyth, G. K. ELDA: Extreme limiting dilution analysis for
comparing depleted and enriched populations in stem cell and other assays. J.
Immunol. Methods 347, 70–78 (2009).
25. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
26. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in
glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
27. Blough, M. D., Beauchamp, D. C., Westgate, M. R., Kelly, J. J. & Cairncross, J.
G. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell
lines and brain tumor initiating cells from glioblastoma. J. Neurooncol. 102,
1–7 (2011).
28. Nagel, Z. D. et al. DNA repair capacity in multiple pathways predicts
chemoresistance in glioblastoma multiforme. Cancer Res. 77, 198–2061
(2017).
29. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in
primary glioblastoma. Science 344, 1396–1401 (2014).
30. Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic
regulation of extrachromosomal mutant EGFR DNA. Science 343, 72–76
(2014).
31. Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour
evolution and genetic heterogeneity. Nature 543, 122–125 (2017).
32. deCarvalho, A. C. et al. Discordant inheritance of chromosomal and
extrachromosomal DNA elements contributes to dynamic disease evolution in
glioblastoma. Nat. Genet. 50, 708–717 (2018).
33. Herting, C. et al. Genetic driver mutations define the expression signature and
microenvironmental composition of high‐grade gliomas. Glia 65, 1914–1926
(2017).
34. Jun, H. J. et al. A PDGFRα-driven mouse model of glioblastoma reveals a
stathmin1-mediated mechanism of sensitivity to vinblastine. Nat. Commun. 9,
3116, https://doi.org/10.1038/s41467-018-05036-4 (2018).
35. Ozawa, T. et al. Most human non-GCIMP glioblastoma subtypes evolve from
a common proneural-like precursor glioma. Cancer Cell 26, 288–300 (2014).
36. Huang, M. et al. Engineering genetic predisposition in human neuroepithelial
stem cells recapitulates medulloblastoma tumorigenesis. Cell Stem Cell 5,
433–446 (2019).
37. Bian, S. et al. Genetically engineered cerebral organoids model brain tumor
formation. Nat. Methods 15, 631–639 (2018).
38. Bachoo, R. M. et al. Epidermal growth factor receptor and Ink4a/Arf:
convergent mechanisms governing terminal differentiation and
transformation along the neural stem cell to astrocyte axis. Cancer Cell 1,
269–277 (2002).
39. Giannini, C. et al. Patient tumor EGFR and PDGFRA gene amplifications
retained in an invasive intracranial xenograft model of glioblastoma
multiforme. Neuro Oncol. 7, 164–176 (2005).
40. Zou, H. et al. Double minute amplification of mutant PDGF receptor alpha in
a mouse glioma model. Sci. Rep. 5, 8468, https://doi.org/10.1038/srep08468
(2015).
41. Camacho, C. V. et al. DNA double-strand breaks cooperate with loss of Ink4
and Arf tumor suppressors to generate glioblastomas with frequent Met
amplification. Oncogene 34, 1064–1072 (2015).
42. Gore, A. et al. Somatic coding mutations in human induced pluripotent stem
cells. Nature 471, 63–67 (2011).
43. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat.
Protoc. 8, 2281–2308 (2013).
44. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
(15–215 (2013).
45. Harrow, J. et al. GENCODE: the reference human genome annotation for The
ENCODE Project. Genome Res. 22, 1760–1774 (2012).
46. Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with
high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
47. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from
RNA-seq data. Genome Res. 22, 2008–2017 (2012).
48. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550, https://doi.
org/10.1186/s13059-014-0550-8 (2014).
49. Anders, S. & Huber, W. Differential expression analysis for sequence count data.
Genome Biol. 11, R106, https://doi.org/10.1186/gb-2010-11-10-r106 (2010).
50. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene
expression data analysis. Genome Biol. 19, 15, https://doi.org/10.1186/s13059-
017-1382-0 (2018).
51. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the
analysis of systems-level datasets. Nat. Commun. 10, 1523, https://doi.org/
10.1038/s41467-019-09234-6 (2019).
Acknowledgements
We thank W.K. Cavenee, A.H. Thorne, C. Zanca, Yeo lab and Furnari lab members for
discussions and helpful suggestions. We are grateful to the IGM Genomics Center,
University of California San Diego for conducting RNA sequencing, digital karyotyping,
single-cell RNA sequencing and whole genome sequencing. We thank D. Pizzo at the
Center for Advanced Laboratory Medicine, University of California San Diego for
assistance with immunohistochemistry. This work was supported by National Institutes
of Health (NIH) R01NS080939 (F.B.F.), R01HL137223 and R01HD85902 (G.W.Y.),
R01GM114362 (V.B. and N.D.N.), P30CA023100 (IGM Genomics Center), the Defeat
GBM Research Collaborative, a subsidiary of the National Brain Tumor Society (F.B.F.
and P.S.M.), Ruth L. Kirschstein Institutional National Research Award T32 GM008666
(A.D.P.), grants from National Institute of Neurological Disorders and Stroke NS73831
(P.S.M.), the Ben and Catherine Ivy Foundation (P.S.M.), and National Science Foun-
dation DBI-1458557 (V.B. and N.D.N.). I.A.C. is a San Diego IRACDA Fellow supported
by NIH/NIGMS K12 GM068524 Award.
Author contributions
T.K. designed the study, conducted the experiments and wrote the paper with inputs
from other authors. I.A.C. performed bioinformatics analyses and wrote the paper. J.A.B.,
A.D.P., K.M.T., F.M.H., J.M., Sh.M. and A.D.B. conducted the experiments. Se.M.
designed the study. R.F.H. and S.S. conducted pathological analyses. M.D. and N.D.N.
performed bioinformatics analyses. J.R., K.A.F., V.B., C.C.C. and P.S.M. supervised parts
of the study. G.W.Y. and F.B.F. conceived the study, wrote the paper with inputs from
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14312-1 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:550 | https://doi.org/10.1038/s41467-020-14312-1 | www.nature.com/naturecommunications 13
other authors, and supervised all aspects of the study. T.K. and I.A.C. contributed equally
to this work. J.A.B. and Se.M. contributed equally to this work.
Competing interests
The authors declare the following competing interests: P.S.M. is a co-founder of
Boundless Bio, Inc. (BB). He has equity interest in the company and serves as the chair of
the Scientific Advisory Board. V.B. is a co-founder, serves on the scientific advisory board
and has an equity interest in BB and Digital Proteomics, LLC (DP), and receives income
from DP. The terms of this arrangement have been reviewed and approved by the
University of California, San Diego in accordance with its conflict of interest policies. BB
and DP were not involved in the research presented here. K.M.T became an employer of
Boundless Bio after submission of this manuscript. G.W.Y. is a co-founder, member of
the Board of Directors, equity holder, and paid consultant for Eclipse BioInnovations.
The terms of these arrangements have been reviewed and approved by the University of
California, San Diego in accordance with its conflict of interest policies. The remaining
authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-14312-1.
Correspondence and requests for materials should be addressed to G.W.Y. or F.B.F.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14312-1
14 NATURE COMMUNICATIONS |          (2020) 11:550 | https://doi.org/10.1038/s41467-020-14312-1 | www.nature.com/naturecommunications
